Table 1 Demographic characteristics of the studies included
Study, year | Location | Group: dose(n) | HbA1c (%) | Sex (M/F) | Age (years) | BMI (kg/m2) | Diabetes duration (months) | Treatment duration (months) | CRPa (mg/L) |
|---|---|---|---|---|---|---|---|---|---|
Derosa,2012a [20] | Italy | sita:100 mg + met:2500 ± 500 mg(91) | sita+met:8.1 ± 0.8 | sita+met:42/49 | sita+met:55.9 ± 8.8 | sita+met:28.1 ± 1.2 | sita+met:5.8 ± 2.6 | 12 | sita+met:-0.5 ± 0.54 |
met:2500 ± 500 mg(87) | met:8.0 ± 0.7 | met:44/43 | met:54.8 ± 7.9 | met:28.9 ± 2.0 | met:5.4 ± 2.3 | pla:-0.4 ± 0.73 | |||
Asahara,2013 [21] | Japan | sita:50 mg(24) | sita:8.3 ± 0.2 | sita:11/13 | sita:62.0 ± 2.3 | sita:25.5 ± 0.9 | NS | 3 | sita:-0.3 ± 0.1 |
pla:50 mg(24) | pla:8.2 ± 0.2 | pla:14/10 | pla:58.0 ± 2.4 | pla:26.5 ± 0.7 | pla:-0.1 ± 0.1 | ||||
Suzuki,2014 [22] | Japan | sita:50 mg(16) | IG:9.1 ± 1.6 | sita:9/7 | sita:56.1 ± 15.3 | sita:26.3 ± 7.2 | sita:22.8 ± 27.6 | 6 | sita:-0.1 ± 0.6 |
lira:0.9 mg(24) | lira:9.8 ± 2.2 | lira:15/9 | lira:58.6 ± 15.9 | lira:28.2 ± 7.2 | lira:28.8 ± 33.6 | lira:-1.9 ± 0.6 | |||
Liu,2013 [23] | Taiwan | sita:100 mg(60) | sita:8.27 ± 0.86 | sita:22/38 | sita:60.1 ± 8.9 | sita:26.6 ± 4.6 | sita:93.6 ± 51.6 | 6 | sita:-0.07 ± 0.04 |
piog:30 mg(60) | piog:8.54 ± 0.97 | piog:23/37 | piog:58.1 ± 8.3 | piog:25.7 ± 3.7 | piog:93.6 ± 46.8 | piog:-0.19 ± 0.04 | |||
Derosa,2010 [24] | Italy | sita:100 mg + piog:30 mg(75) | sita+piog:8.5 ± 0.9 | sita+piog:37/38 | sita+piog:57.0 ± 5.0 | sita+piog:27.9 ± 1.5 | sita+piog:5.0 ± 2.0 | 12 | sita+piog:-0.7 ± 0.8 |
met:850 mg + piog:30 mg(76) | met+piog:8.4 ± 0.8 | met+piog:39/37 | met+piog:58.0 ± 6.0 | met+piog:27.7 ± 1.3 | met+piog:6.0 ± 3.0 | met+piog:-0.7 ± 0.71 | |||
Nakamura,2014 [25] | Japan | sita:50 mg(24) | sita:7.04 ± 0.56 | sita:10/14 | sita:66.6 ± 11.9 | sita:27.8 ± 3.5 | sita:57.6 ± 41.2 | 3 | sita:-1.0 ± 3.6 |
vog:0.6 mg(31) | vog:6.94 ± 0.45 | vog:18/13 | vog:68.4 ± 9.2 | vog:25.7 ± 4.3 | vog:41.9 ± 44.1 | vog:1.2 ± 5.6 | |||
Derosas,2012b [26] | Italy | vild:100 mg + met:2500 ± 500 mg(84) | vild+met:8.1 ± 0.6 | vild+met:42/42 | vild+met:54.2 ± 8.3 | vild+met:27.9 ± 1.5 | vild+met:6.1 ± 3.7 | 12 | vild+met:-0.8 ± 1.4 |
Pla + met:2500 ± 500 mg(83) | pla + met:8.2 ± 0.7 | pla + met:43/40 | pla + met:52.4 ± 7.1 | pla + met:27.8 ± 1.4 | pla + met:6.3 ± 3.9 | pla + met:-0.4 ± 0.7 | |||
Strozik,2014 [27] | Poland | vild:100 mg + met:1500 mg(15) | vild+met:8.2 ± 0.2 | vild+met:10/5 | vild+met:45.9 ± 4.6 | vild+met:28.2 ± 1.8 | vild+met:24~60 | 3 | vild+met:-0.49 ± 0.2 |
met:1500 mg(13) | met:8.0 ± 0.6 | met:9/4 | met:51.4 ± 7.2 | met:29.0 ± 3.5 | met:24~60 | met:-0.06 ± 0.3 | |||
Zografou,2015 [28] | Greece | vild:50 mg + met:850 mg(32) | vild+met:8.1 ± 0.8 | vild+met:18/14 | vild+met:52.0 ± 11.2 | vild+met:31.6 ± 4.6 | NS | 6 | vild+met:-0.4 ± 2.8 |
met:850 mg(32) | met:8.0 ± 0.8 | met:20/12 | met:56.0 ± 10.5 | met:32.2 ± 5.9 | met:1.1 ± 1.6 | ||||
Derosa,2014 [29] | Italy | vild:100 mg(86) | vild:7.9 ± 0.9 | vild:42/44 | vild:59.8 ± 9.9 | vild:27.9 ± 1.6 | vild:6.9 ± 4.7 | 6 | vild:-0.4 ± 0.6 |
glim:6 mg(70) | glim:7.8 ± 0.8 | glim:36/34 | glim:56.8 ± 8.9 | glim:27.7 ± 1.3 | glim:6.7 ± 3.5 | glim:-0.3 ± 0.6 | |||
Kim,2017 [30] | Korea | vild:50 mg(14) | vild:7.2 ± 0.2 | vild:9/5 | vild:59.9 ± 10.2 | vild:25.8 ± 2.7 | NS | 4 | vild:-0.18 ± 1.1 |
piog:15 mg(11) | piog:7.4 ± 0.4 | piog:4/7 | piog:52.1 ± 11.1 | piog:27.4 ± 4.3 | piog:-0.55 ± 0.9 | ||||
Mita,2015 [31] | Japan | alo:25 mg(172) | alo:7.3 ± 0.8 | alo:101/71 | alo:64.4 ± 9.8 | alo:24.6 ± 4.3 | alo:9 ± 3.3 | 26 | alo:0.06 ± 0.1 |
con:25 mg(169) | con:7.2 ± 0.8 | con:98/71 | con:64.8 ± 9.1 | con:24.9 ± 3.7 | con:8.2 ± 3.7 | con:0 ± 0 | |||
Boer,2017 [32] | Netherland | lin:5 mg(22) | lin:6.3 ± 0.4 | lin:13/9 | lin:63 ± 4.7 | lin:32.3 ± 3.5 | lin:18 ± 20 | 6.5 | lin:-0.2 ± 0.7 |
pla:5 mg(22) | pla:6.2 ± 0.5 | pla:14/8 | pla:62 ± 4.3 | pla:29 ± 2.3 | pla:12 ± 13 | pla:0.5 ± 1.0 | |||
Yamada,2017 [33] | Japan | sita:50 mg(55) | sit:7.0 ± 0.6 | sit:38/17 | sit:69 ± 8 | sit:25.9 ± 3.3 | NS | 24 | sit:-0.06 ± 0.28 |
con:50 mg(60) | con:6.9 ± 0.5 | con:39/21 | con:69 ± 9 | con:24.8 ± 3.9 | con:-0.09 ± 0.46 | ||||
Koren,2012 [34] | Israel | sita:100 mg(20) | NS | NS | NS | NS | NS | 3 | sita:0.9 ± 1.9 |
glib:5 mg(20) | glib:0.29 ± 1.7 | ||||||||
Nogueira,2014 [35] | Brazil | sita:100 mg(18) | sit:8.0 ± 0.6 | sit:9/9 | sit:55.1 ± 6.7 | sit:26.5 ± 2.7 | sit:130.8 ± 69.6 | 6 | sit:-0.7 ± 2.8 |
insu:11 ± 6.7(17) | insu:8.1 ± 0.7 | insu:6/11 | insu:58.4 ± 6.9 | insu:27.5 ± 2.5 | insu:130.8 ± 90 | insu:-0.1 ± 2.2 |